Nika BioTechnology Inc
Nika Pharmaceuticals, Inc., a pharmaceutical company, develops drugs for the treatment of HIV/AIDS, hepatitis B and C, rheumatoid arthritis, cancer, diabetes, and various other diseases. It offers dietary supplements and antiviral drugs, as well as thymus nuclear glycoprotein for the treatment of HIV. The company was formerly known as Centennial Growth Equities Inc. and changed its name to Nika P… Read more
Nika BioTechnology Inc (NIKA) - Total Assets
Latest total assets as of September 2025: $23.62K USD
Based on the latest financial reports, Nika BioTechnology Inc (NIKA) holds total assets worth $23.62K USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Nika BioTechnology Inc - Total Assets Trend (2016–2024)
This chart illustrates how Nika BioTechnology Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Nika BioTechnology Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Nika BioTechnology Inc's total assets of $23.62K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Nika BioTechnology Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nika BioTechnology Inc's current assets represent 100.0% of total assets in 2024, unchanged from 100.0% in 2016.
- Cash Position: Cash and equivalents constituted 11.6% of total assets in 2024, down from 100.0% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Nika BioTechnology Inc Competitors by Total Assets
Key competitors of Nika BioTechnology Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Nika BioTechnology Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Nika BioTechnology Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Nika BioTechnology Inc is currently not profitable relative to its asset base.
Nika BioTechnology Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.08 | 0.01 | 0.95 |
| Quick Ratio | 0.08 | -0.06 | 0.95 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-260.54K | $ -208.78K | $ -160.00 |
Nika BioTechnology Inc - Advanced Valuation Insights
This section examines the relationship between Nika BioTechnology Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 15077.45 |
| Asset Growth Rate (YoY) | -8.5% |
| Total Assets | $17.93K |
| Market Capitalization | $270.40 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Nika BioTechnology Inc's assets at a significant premium ( 15077.45x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Nika BioTechnology Inc's assets decreased by 8.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Nika BioTechnology Inc (2016–2024)
The table below shows the annual total assets of Nika BioTechnology Inc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $17.93K | -8.48% |
| 2023-12-31 | $19.60K | +2168.06% |
| 2022-12-31 | $864.00 | +116.54% |
| 2021-12-31 | $399.00 | -75.23% |
| 2020-12-31 | $1.61K | +7222.73% |
| 2019-12-31 | $22.00 | -66.67% |
| 2018-12-31 | $66.00 | -97.35% |
| 2017-12-31 | $2.49K | +1973.33% |
| 2016-12-31 | $120.00 | -- |